Henry Brem, MD

Henry Brem is the Harvey Cushing Professor of Neurosurgery at The Johns Hopkins University, Director of the Department of Neurosurgery, and Neurosurgeon-in-Chief. He also is a professor of Oncology, Ophthalmology, and Biomedical Engineering. Brem received his undergraduate degree from New York University, his medical degree from Harvard, and trained in neurosurgery at Columbia. He has built one of the largest brain tumor research and treatment centers in the world. He has trained numerous researchers who have revolutionized the fields of intraoperative imaging, angiogenesis, immunotherapy, and controlled release polymers for drug delivery to the brain. His work has been continuously funded by the NIH since 1982 and is currently funded by several active grants. He has published over 350 research papers, 57 book chapters, 11 patents, and an H index of 93 with over 35,000 citations.

Dr. Brem is committed to collaboration across disciplines to inspire and facilitate the translation of scientific advances for direct patient benefit. As such, he has helped found Johns Hopkins Brain Science Institute and was co-principal investigator of the Johns Hopkins Coulter Foundation “Translational Research Partners Program” which funded innovative biomedical engineering projects across disciplines that have the potential to rapidly develop into useful products for patients. Henry Brem has developed new tools and techniques that have changed the field of neurosurgery. Brem carried out the pivotal clinical study that introduced navigational imaging into the neurosurgical suite. His work led to the FDA’s approval of the first image guidance computer system for intraoperative localization of tumors. Furthermore, he has changed the surgical armamentarium against brain tumors by inventing and developing Gliadel® wafers to intraoperatively deliver chemotherapy to brain tumors.

https://www.hopkinsmedicine.org/profiles/details/henry-brem

LinkedIn Profile

Robert Storey

Bob Storey is a managing partner at The LaunchPort™, a medtech manufacturing accelerator. He has extensive experience in working with NIH initiatives in innovation and investment. He is one of the eight national portfolio managers for the NIBIB RADx program and has been the sole medical device instructor for the biannual national NIH I-Corps program since its inception in 2014. These activities, combined with operations of LaunchPort, have resulted in the assessment of hundreds of early stage medtech and life sciences companies and technologies each year. Storey’s involvement with Johns Hopkins University and its School of Medicine has included a number of neuroscience and technology deployments. LaunchPort, under Storey’s leadership, will support NeuroTech Harbor’s equitech vision and its innovators.

LinkedIn Profile

Kebreten Manaye, MD

Dr. Kebreten Manaye is a professor and currently serves as the Chair of the Physiology Department at Howard University Medical School. An accomplished neuroscientist, her research is centered on elucidating the underlying mechanisms of neurological and neurodegenerative conditions associated with brain aging. Dr. Manaye is a PI which is supported by private foundation funding and contributes significantly to advancing the fields of computational neuroscience and neurotechnology. In her capacity as Principal Investigator at NeuroTech Harbor, Dr. Manaye leads the innovative Pathways program,

Dr. Manaye is highly esteemed for her mentorship and dedication to her graduate and medical students. In 2023, she made history by being elected as a President of the Association of Chairs of Physiology Departments, underscoring her leadership and influence within the academic community. Through her unwavering commitment to scientific advancement and education, Dr. Manaye continues to inspire the emergence of the next generation of neuroscientist and innovators in the field.

LinkedIn Profile

Evaristus Nwulia, MD, MHS

Evaristus Nwulia, M.D. MHS, is a Johns Hopkins trained physician and a neuroscientist, with over 15 years history in leading educational and training programs aimed at enhancing participation in STEM and MD-Ph.D. students from HBCUs in the neuroscience workforce. He is also a Professor of Neuroscience at Howard University, who pioneered the development of home-based olfactory sensory stimulation platforms as disease modifying interventions for early Alzheimer’s disease. He holds several patents for devices and drugs, and for olfactory transcellular drug delivery methods for CNS disorders. He is co-Founder of three neuromedical device companies, including Evon Medics LLC, a neuroTech company tackling neurodegenerative diseases, traumatic brain injuries and chronic pain; Evon Medics has become a harbor for nurturing career development of highly talented young innovators. Evaristus has been a member of several NIH neuroscience-based scientific peer review panels over the past 10 years and has chaired the NIH Fogarty Global Brain Disorders Special Emphasis Panel. Ergo, he has extensive experience for recognition of projects with potential transformative impact. As a Neuroethicist and Chair of the Institutional Ethics Committee Board at Howard University, he brings substantial expertise in the ethical, legal, and societal implications of neuroscience and neurotech devices, particularly from the standpoint of all populations affected by the devices.

LinkedIn Profile